TrialJournal for immunotherapy of cancer2023

Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer.

Douglas G McNeel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.